Physician

Jonathan Christopher Bender, M.D.

According to 2025 Medicare claims, Jonathan Bender, M.D. (NPI: 1649228651) practices hematology/oncology in the Atlanta-Sandy Springs-Roswell, GA market, with the plurality of this provider's patient population coming from Fayette, GA. This provider's primary affiliated billing organization is PIEDMONT CANCER INSTITUTE PC (NPI: 1336180637; TIN: 581761689) and primary practice location at 30214-2112.

Bender's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 789 traditional Medicare patients, billed 267,603 HCPCS/CPT codes, and received $5,078,252 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 3,465 prescription claims across 513 beneficiaries totaling $9,008,016 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 52 claims. Open Payments data shows 34 records totaling $805. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,837,393 to $5,078,252. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $3,303,421 to $9,008,016. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $8,161 to $1,100.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	910	247,290	$2,837,393
2016	882	276,826	$3,481,097
2017	910	342,204	$3,839,950
2018	933	296,775	$4,619,564
2019	918	336,701	$4,985,503
2020	877	402,919	$5,746,863
2021	830	403,971	$6,101,345
2022	799	287,622	$5,157,207
2023	752	260,085	$5,267,629
2024	789	267,603	$5,078,252

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	394	3,803	$3,303,421
2016	381	3,507	$3,529,955
2017	425	3,892	$4,201,794
2018	427	3,747	$4,801,628
2019	433	3,836	$6,457,740
2020	454	3,768	$7,472,578
2021	480	3,644	$7,805,765
2022	494	3,332	$6,908,369
2023	502	3,358	$7,213,781
2024	513	3,465	$9,008,016

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	85	$6,051
2016	N/R	110	$16,725
2017	N/R	66	$10,035
2018	N/R	40	$5,076
2019	N/R	75	$25,926
2020	N/R	56	$4,942
2021	N/R	97	$7,304
2022	N/R	106	$3,499
2023	N/R	52	$12,197
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	120	530	$92
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	237	653	$90
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	388	548	$59
96372	Injection of drug or substance under skin or into muscle	150	652	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	514	1,386	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	80	2,121	$1,327,473
Pomalyst	Pomalidomide	51	1,428	$1,164,828
Imbruvica	Ibrutinib	70	1,960	$1,120,557
Cabometyx	Cabozantinib S-Malate	26	780	$692,847
Ibrance	Palbociclib	37	1,036	$584,349

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	34	$805	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jonathan Christopher Bender, M.D.?

Tedicare shows public-source Medicare data for Jonathan Christopher Bender, M.D. (NPI 1649228651), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jonathan Christopher Bender, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Jonathan Christopher Bender, M.D.?

Jonathan Christopher Bender, M.D. is linked to PIEDMONT CANCER INSTITUTE PC (billing NPI 1336180637) in the available physician profile data.

Does Jonathan Christopher Bender, M.D. have Open Payments data?

Jonathan Christopher Bender, M.D. has 34 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.